Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_assertion type Assertion NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_head.
- NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_assertion description "[Similar as tunicamycin, treatment with RES lead to the activation of all 3 branches of the UPR, with early splicing of XBP-1 indicative of IRE1 activation, phosphorylation of eIF2alpha consistent with ER resident kinase (PERK) activation, activating transcription factor 6 (ATF6) splicing, and increase in expression levels of the downstream molecules GRP78/BiP, GRP94 and CHOP/GADD153 in human Burkitt's lymphoma Raji and Daudi cell lines.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_provenance.
- NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_assertion evidence source_evidence_literature NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_provenance.
- NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_assertion SIO_000772 20723265 NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_provenance.
- NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_assertion wasDerivedFrom befree-20150227 NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_provenance.
- NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_assertion wasGeneratedBy ECO_0000203 NP778831.RAZHQE_Hlf5VkapaO-nwBX5X8V5FahxaZ_ded6pg6MVJE130_provenance.